Clinical Scoring Systems in Cystic Fibrosis – What Are the Options for Developing Countries?

Brenda Morrow

doi:10.17795/compreped-13158

Clinical Scoring Systems in Cystic Fibrosis – What Are the Options for Developing Countries?

authors:

Brenda Morrow ^{1
, *}

1 Department of Pediatric Medicine, University of Cape Town, Cape Town, South Africa

how to cite: Morrow B. Clinical Scoring Systems in Cystic Fibrosis – What Are the Options for Developing Countries?. J Compr Ped. 2013;4(4):e93768. https://doi.org/10.17795/compreped-13158.

Abstract

Cystic fibrosis (CF) is recognized as a serious, life-limiting autosomal recessive inherited condition, affecting multiple organs. Improvements in both diagnosis and management of CF has led to the recognition of a range of phenotypes, from mild to severe, with varying rates of disease progression. Pulmonary disease is still the main predictor of morbidity and mortality associated with CF (1). There are currently nearly 2000 recognized cystic fibrosis trans-membrane regulator (CFTR) mutations.

Keywords

Cystic Fibrosis Shwachman

Fulltext

References

1.
The references are available in PDF file.

comments

article information

Clinical Scoring Systems in Cystic Fibrosis – What Are the Options for Developing Countries?

Abstract

Keywords

Fulltext

References

Copyright